← Back to home

ADVANCED (STAGE IIIB/IV) NON-SMALL CELL LUNG CANCER (NSCLC) WITH MET EXON 14 (METEX14) SKIPPING ALTERATIONS OR MET AMPLIFICATION

Clinical trials for ADVANCED (STAGE IIIB/IV) NON-SMALL CELL LUNG CANCER (NSCLC) WITH MET EXON 14 (METEX14) SKIPPING ALTERATIONS OR MET AMPLIFICATION explained in plain language.

Never miss a new study

Get alerted when new ADVANCED (STAGE IIIB/IV) NON-SMALL CELL LUNG CANCER (NSCLC) WITH MET EXON 14 (METEX14) SKIPPING ALTERATIONS OR MET AMPLIFICATION trials appear

Sign up with your email to follow new studies for ADVANCED (STAGE IIIB/IV) NON-SMALL CELL LUNG CANCER (NSCLC) WITH MET EXON 14 (METEX14) SKIPPING ALTERATIONS OR MET AMPLIFICATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Targeted drug shows promise against tough lung cancer subtype

Disease control Ongoing

This study tested whether the drug tepotinib could control advanced lung cancer in people whose tumors have specific genetic changes (MET alterations). Researchers enrolled 337 adults with advanced non-small cell lung cancer to take tepotinib daily and measured how well it shrank…

Matched conditions: ADVANCED (STAGE IIIB/IV) NON-SMALL CELL LUNG CANCER (NSCLC) WITH MET EXON 14 (METEX14) SKIPPING ALTERATIONS OR MET AMPLIFICATION

Phase: PHASE2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control

Last updated Apr 04, 2026 04:06 UTC

ADVANCED (STAGE IIIB/IV) NON-SMALL CELL LUNG CANCER (NSCLC) WITH MET EXON 14 (METEX14) SKIPPING ALTERATIONS OR MET AMPLIFICATION

Get alerted when new ADVANCED (STAGE IIIB/IV) NON-SMALL CELL LUNG CANCER (NSCLC) WITH MET EXON 14 (METEX14) SKIPPING ALTERATIONS OR MET AMPLIFICATION trials appear

Targeted drug shows promise against tough lung cancer subtype